ReviewTherapeutic advances in respiratory disease2015
Emerging therapies for the prevention of acute respiratory distress syndrome.
Review in Therapeutic advances in respiratory disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- The preventive effect of antiplatelet therapy in acute respiratory distress syndrome: a meta-analysis.Critical care (London, England) · 2018Pooled it
- Cardiosphere-derived cells in the primary prevention of sepsis-induced acute lung injury in pigs.PloS one · 2026Article
- The Alleviation of LPS-Induced Murine Acute Lung Injury by GSH-Mediated PEGylated Artesunate Prodrugs.Frontiers in pharmacology · 2022Article
- A digital health platform for assisting the diagnosis and monitoring of COVID-19 progression: An adjuvant approach for augmenting the antiviral response and mitigating the immune-mediated target organ damage.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- Mechanism of Anti-Inflammatory Activity of TLR4-Interacting SPA4 Peptide.ImmunoHorizons · 2021Article
- Effect of systemic photobiomodulation in the course of acute lung injury in rats.Lasers in medical science · 2021Article
- Are losartan and imatinib effective against SARS-CoV2 pathogenesis? A pathophysiologic-based in silico study.In silico pharmacology · 2021Article
- Basic Critical Care for Management of COVID-19 Patients: Position Paper of Indian Society of Critical Care Medicine, Part-I.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2020Review
- Acute respiratory distress syndrome in acute pancreatitis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020Review
- Combination of C21 and ARBs with rhACE2 as a therapeutic protocol: A new promising approach for treating ARDS in patients with coronavirus infection.Medical journal of the Islamic Republic of Iran · 2020Article
- Photobiomodulation modulates the resolution of inflammation during acute lung injury induced by sepsis.Lasers in medical science · 2019Article
- Inflammation and Monocyte Recruitment due to Aging and Mechanical Stretch in Alveolar Epithelium are Inhibited by the Molecular Chaperone 4-phenylbutyrate.Cellular and molecular bioengineering · 2018Article
- 25-Hydroxycholesterol protects against acute lung injury via targeting MD-2.Journal of cellular and molecular medicine · 2018Article
- Article
- Beneficial effects of Red Light-Emitting Diode treatment in experimental model of acute lung injury induced by sepsis.Scientific reports · 2017Article
- Acute respiratory distress syndrome.European respiratory review : an official journal of the European Respiratory Society · 2017Review
- Lugrandoside attenuates LPS-induced acute respiratory distress syndrome by anti-inflammation and anti-apoptosis in mice.American journal of translational research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The development of acute respiratory distress syndrome (ARDS) carries significant risk of morbidity and mortality. To date, pharmacological therapy has been largely ineffective for patients with ARDS. We present our personal review aimed at outlining current and future directions for the pharmacological prevention of ARDS. Several available risk-stratification or prediction score strategies for identification of patients at risk of ARDS have been reported. Although not ready for clinical everyday use, they are and will be instrumental in the ongoing and future trials of pharmacoprevention of ARDS.Several systemic medications established the potential role in ARDS prevention based on the preclinical studies and observational data. Due to potential for systemic adverse effects to neutralize any pharmacological benefits of systemic therapy, inhaled medications appear particularly attractive candidates for ARDS prevention. This is because of their direct delivery to the site of proposed action (lungs), while the pulmonary epithelial surface is still functional.We postulate that overall morbidity and mortality rates from ARDS in the future will be contingent upon decreasing the overall incidence of ARDS through effective identification of those at risk and early application of proven supportive care and pharmacological interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.